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Abstract  1 
Background: The cost of current standard Ready-to-Use Therapeutic Food (RUTF) is 2 
among major obstacles to the scale up of Community-based Management of Acute 3 
Malnutrition (CMAM), an important child survival strategy. Identifying a cheaper 4 
alternative is a global public health priority.  5 
Objective: We compare the efficacy of Soya-Maize-Sorghum RUTF (SMS-RUTF) with that 6 
of standard RUTF (P-RUTF). 7 
Design: This was a non-blinded, parallel group, simple randomised, controlled trial that 8 
enrolled two groups of SAM children (6 and 23 months and 24 – 59 months) and used a 9 
day care approach.   10 
Results: Intention-to-treat (ITT) and per protocol (PP) analyses showed non-inferiority 11 
of  SMS-RUTF compared to P-RUTF for recovery rate [Δ =-2.0%(95%CI -7.6, 3.6) in ITT 12 
and -1.9%(95%CI -5.3, 1.4) in PP], weight gain [Δ=-0.7gkg
-1
day
-1
 (95%CI -1.3, 0.0)] and 13 
Length of stay [Δ=2.0(95% CI, −1.7, 5.8)days] in  children ≥24months. In children ≤23 14 
months, recovery rate with SMS-RUTF was inferior to that with P-RUTF [Δ=-20.8% 15 
(95%CI -29.9, -11.7) in ITT and -17.2%(95%CI –25.6, -8.7) in PP].   Treatment with SMS-16 
RUTF resulted in a greater increase in hemoglobin [0.670(0.420, 0.921)g dl-1; p<0.001]. 17 
Treatment with both RUTFs resulted in the replenishment of all the amino acids tested, 18 
except for methionine. There were no differences at discharge between RUTF groups in 19 
fat mass [Δ=0.3(95%CI –0.6, 1.6) kg; p=0.341] of fat mass index [Δ=0.4(95%CI –0.3, 1.1) 20 
kg m
-2
; p=0.262]. By contrast, comparisons of fat free mass indicated lower levels of FFM 21 
than the community controls after treatment with either of the two RUTFs [Δ=-22 
1.3(95%CI –2.4, -0.1)kg; p=0.034 for comparison between community controls and the 23 
SMS-RUTF group and Δ=-1.8(95%CI –2.9, -0.6)kg; p=0.003 for comparison between 24 
community controls and the P-RUTF group]. 25 
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Conclusion: SMS-RUTF can be used to treat SAM in children ≥24 months of age to 26 
reduce the costs of CMAM programmes.   More research is required to optimize SMS-27 
RUTF for younger children.  28 
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Introduction 29 
 30 
Severe Acute Malnutrition (SAM) affects approximately 19 million children under the age of 31 
5 and is associated with over half million preventable child deaths each year(1). This figure 32 
does not include the edematous form of SAM. Previous figures including all the forms of 33 
SAM have suggested much higher burden (2). In most developing countries, Case Fatality 34 
Rates in hospitals treating SAM remain at 20-30% and few of those requiring care actually 35 
access treatment (2). Community-based management of SAM (CMAM) has been developed 36 
to offer a new approach to delivering care to acutely malnourished children in emergency 37 
situations and in more stable settings. The model is rooted in public health principles of 38 
coverage and access and is designed to achieve population-wide impact (3). It focuses 39 
primarily on treatment of the majority of the acutely malnourished people as outpatients in 40 
their homes rather than in Therapeutic Feeding Centers (3). Intensive inpatient care is also 41 
provided for those who have complications(3). Techniques of community mobilization are 42 
used to engage the affected population and achieve high proportion of early presentation 43 
while maximizing coverage(3). A study conducted in Malawi on SAM children treated using 44 
Ready-to Use Therapeutic Food  (RUTF) have also demonstrated that the majority (over 45 
85%) of children discharged as recovered after treated using the CMAM approach maintained 46 
a normal weight for height for as long as 15 months after discharge (4). 47 
 48 
RUTF, a lipid-based paste that is energy dense, resists bacterial contamination, and requires 49 
no cooking(5), is a central element of CMAM programs. The production of RUTF requires 50 
grinding all ingredients to a particle size of < 200 microns and embedding the protein and 51 
carbohydrate components into a lipid matrix(5).  The production process avoids the 52 
introduction of water and the resultant low water activity in the product is critical to RUTF’s 53 
resistance towards bacterial contamination.  This in turn allow RUTF to be safely store at 54 
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ambient temperatures and used in poor communities (5). The most widely used RUTF 55 
referred as P-RUTF in this paper, is a mixture of milk powder, sugar, vegetable oil, peanut 56 
butter, vitamins, and minerals(5;6). It is equivalent to the WHO F-100 milk(7).  This RUTF 57 
recipe has been used widely in CMAM to treat severely malnourished children in resource-58 
poor settings(8) with demonstrably high recovery rates, low case-fatalities, and greater weight 59 
gain has been demonstrated using P-RUTF(2;9;10).  However, the high milk content of this 60 
formulation makes it very expensive for sustainable use in resource-poor settings and 61 
increases the proportion of ingredients that have to be imported into developing countries.  62 
 63 
To lower the cost and increase the potential for using locally grown ingredients, Valid 64 
Nutrition has developed a new milk-and peanut free recipe based on locally produced crops.  65 
This recipe is made from Soya, Maize and Sorghum (SMS-RUTF), and may provide a 66 
cheaper alternative to the P-RUTF currently used.  However, the efficacy of this formulation 67 
compared to P-RUTF has not been formally demonstrated. An initial study assessing the 68 
effectiveness of SMS-RUTF in Lusaka yielded inconclusive results with the recovery rates in 69 
both the intervention and the standard group below international SPHERE standard and an 70 
unexplained high level of mortality(11). Likely explanations of the inconclusive results 71 
included the cholera and measles epidemics and floods that occurred during the study period 72 
causing abnormal increases in mortality and default rates(11).  Despite these inconclusive 73 
results, lessons learned from that trial have been used to improve both the composition of the 74 
SMS-RUTF and the design of studies used to evaluate it.   75 
 76 
The study reported here examined the efficacy of SMS-RUTF compared to P-RUTF using a 77 
design and context that minimized operational constraints.  The SMS-RUTF product used had 78 
an enhanced phytic acid and iron and phytic acid and zinc molar ratios and  improved omega-79 
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6 amega-3 fatty acid profile ratio (11) compared to the product tested in Lusaka.  The study 80 
also included a comparison of changes in hemoglobin, amino acid profile and body 81 
composition during recovery in addition to the standard outcome indicators of recovery rate, 82 
weight gain and length of stay. The hypotheses assumed are that SMS-RUTF is not inferior to 83 
P-RUTF for recovery rate, weight gain and LOS and that treatment with SMS-RUTF will be   84 
associated with higher hemoglobin increase.  85 
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Methods 86 
Study design 87 
Primary objectives 88 
This was a non-blinded, parallel group, simple randomized, controlled trial to compare the 89 
efficacy of SMS-RUTF with that on P-RUTF in the treatment of SAM in two groups of 90 
children, those aged between 6 and 23 months and those aged between 24 – 59 months.  The 91 
non-inferiority hypothesis was chosen because the overall aim of the research was  to develop 92 
a RUTF as effective as the highly effective standard RUTF but cheaper and was assumed 93 
based on the result of a previous study into SMS-RUTF undertaken by this team in Lusaka, 94 
Zambia(11).  Differences in the color and taste between the SMS-RUTF and the P-RUTF 95 
precluded blinding the study. To ensure that the research team had full control over all 96 
treatment parameters and could collect daily data on morbidity, a day care approach was used, 97 
wherein study subjects attended an outpatient treatment center for 8 hours each day to receive 98 
standardized treatment protocols. This day-care approach eliminated the risks that subjects 99 
shared or sold the RUTF and the risk that the energy and micronutrient densities of the RUTF 100 
was altered by inappropriate mixing with other food.  The day care approach also helped 101 
improve the assessment of the adherence to the study protocol and accurately quantifying 102 
individual daily intakes of RUTF.  103 
Secondary objectives 104 
The study also compared changes in hemoglobin, the replenishment of amino stores and 105 
changes in body composition attributable to the two products.  Hemoglobin was measured at 106 
admission and at discharge from the study and in a sub-sample of participants selected 107 
randomly throughout the study period.  The replenishment of amino-acid stores was assessed 108 
by measuring plasma level of the free amino acids (lysine, valine, tryptophan, tyrosine, 109 
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phenylalanine, methionine and cysteine) in overnight-fasted malnourished children before 110 
starting nutrition rehabilitation, upon discharge from the study and in age / sex matched non-111 
wasted community controls recruited from the same area as the malnourished participants. 112 
Body composition was assessed using two techniques. Deuterium Dilution Technique (DDT) 113 
was used to assess Total Body Water (TBW), Fat Free Mass (FFM) and Body Fat Mass (FM).  114 
This sub-study used the change in the concentration of deuterium in samples of saliva after an 115 
intake of a standardized oral dose of Deuterium oxide to estimate TBW and FM and FFM and 116 
derived indexes.  It was conducted in a sub-sample of study subjects at discharge and 117 
compared to the levels found in age and sex matched non-wasted community controls.  118 
Bioelectrical Impedance Analysis (BIA) was used to also estimate TBW, FM, FFM, and 119 
derived indexes. Other specific BIA parameters of Reactance and Resistance (Phase angle, 120 
Wellness Marker), were also measured.  These were assessed using a dual frequency portable 121 
Bodystat 1500MDD in another randomly selected sub-sample of children aged 24 - 59 122 
months drawn from each of the treatment groups.  These children were assessed at the 123 
beginning of nutrition rehabilitation, then again when their MUAC reached 12.5cm and again 124 
at exit from the study.  125 
Setting 126 
The study was undertaken in Miti-Murhesa Health Zone (HZ) located in the Kabare 127 
administrative zone of South Kivu province in Democratic Republic of Congo. The HZ 128 
covers an area of 525 km2 adjacent to Lake Kivu and consists of highland plains and hills at 129 
elevations ranging between 900–1900m.  It has a tropical highland climate.  At the last census 130 
in 2011, it had a recorded population of 204,368 with a very high population density of 392 131 
inhabitants per km2. The main economic activities are subsistence agriculture and small scale 132 
trading. In 2011 the HZ had 40,000 children aged 6 to 59 months with a prevalence of SAM 133 
in these children of 2.2%(12). Breastfeeding is universal but the prevalence of exclusive 134 
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breastfeeding until 6 months is low with the average duration being 2.5 months (13;14). The 135 
diet of infant and young children has remained unchanged for decades and is poor in diary 136 
and other animal source foods(15). The HZ has 16 health centers (HCs) and 4 hospitals and 137 
before the study started was running a limited CMAM program with 3 outpatient sites for the 138 
management of uncomplicated SAM and one stabilization center for the management of SAM 139 
with complications.  The geographical coverage of this program and the number of 140 
admissions were however very low and between May - August 2011 only 40 SAM children 141 
were admitted into the CMAM program out of a predicted case load of over 800. This study 142 
was implemented in 10 out the 16 HCs and used one of the hospitals as a referral center for 143 
the stabilization of SAM with complications.  144 
Study populations  145 
The study participants were selected from children admitted into the government run CMAM 146 
program in Miti-Murhesa HZ.  The government CMAM program admitted all children aged 147 
between 6 and 59 months diagnosed with SAM (mid upper arm circumference [MUAC] 148 
<115mm or bilateral pitting edema of any degree). Length or height was measured but the 149 
related nutrition indices were not used either in decision to admit or discharge children or in 150 
in the definition of outcome. Children with MUAC < 115mm and good appetite and no 151 
medical complication and those with bilateral pitting edema assessed as + or ++ who also had 152 
good appetite and no medical complication were admitted directly into the day-care 153 
component of the study program.  Those with bilateral pitting edema assessed as +++ degree 154 
or with any medical complication at enrolment were referred to the participating inpatient 155 
facility where they received inpatient care until stabilized, after which time they were 156 
admitted into the day-care study program.  Children with any medical or nutritional 157 
complication during follow up were also referred to the participating inpatient facility for 158 
appropriate treatment of the complication, after which they were re-admitted into the day-care 159 
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program and remained in their original study group.  Medical complications were defined 160 
using the World Health Organization’s CMAM and Integrated Management of Childhood 161 
Illness (IMCI) standard definitions (2;16). Nutrition rehabilitation during inpatient followed 162 
the national guidelines and therapeutic milks F75 and F100 were used as appropriate.  163 
 164 
Study subjects were admitted into the study at the same time as they were admitted into the 165 
day care phase of the study program.  Great attention was given to avoid the admission into 166 
the study of any children who were not suffering from SAM and before inclusion in the study, 167 
all potential subjects were re-examined by senior supervisors (all of whom had over 10 years 168 
experience in the diagnosis and management of SAM) to confirm that the diagnosis of SAM 169 
was correct.  The presence of edema, the most difficult to assess diagnostic criteria for SAM, 170 
was confirmed by the senior supervisor prior to enrolment into the study.  Children admitted 171 
into the CMAM program for whom senior supervisors did not confirm presence of edema 172 
were excluded from the study.  Children with congenital or acquired disorders affecting 173 
growth, any history of any food allergy, a history of treatment for SAM in the previous 3 174 
months and those from visiting families were also excluded. 175 
 176 
The community control groups for the body composition and amino acid studies were 177 
recruited from the same neighborhoods as the malnourished children included in the main 178 
study.  These controls were matched for the age at enrolment (± 1 month) and the gender of 179 
the malnourished child.  Technical difficulties in conducting the BIA assessments in children 180 
younger than 24 months meant that only children aged 24 - 59 months and above were 181 
eligible for inclusion in the BIA component. 182 
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Randomization 183 
The study used simple randomization (ratio 1:1). After confirming eligibility for inclusion in 184 
the study, children were randomized by a closed envelope method to receive either SMS-185 
RUTF or P-RUTF. A computer-generated sequentially numbered randomization list (with 186 
variable block sizes) that contained both allocations and codes for 900 children was pre-187 
prepared by the trial statistician who was based outside the DRC.  These were sent to the 188 
national study coordinator who then prepared 900 opaque, sealed, and consecutively 189 
numbered randomization envelops. A block of 20 envelopes were distributed to the 190 
enumerator team leaders at each study site who used them to allocate a “Study Group” to each 191 
subject at admission. The team involved in the assessment of the child for eligibility and in 192 
their follow up had no role in the allocation of the Study Group.  193 
Monitoring and follow up 194 
The study was conducted in specially built “study day care sites” erected at each of the 195 
participating health centers (HCs).  After enrolment, caregivers were asked to bring the 196 
children to nearest site every day between 8am – 4pm until discharged and the mother or 197 
another family member had to stay with the child.  At each site, a minimum of two HC nurses 198 
and one field nutritionist monitored the children’s clinical and nutrition parameters, including 199 
checking the progress of nutritional recovery and identifying and treating any concurrent 200 
infection. At each site, two study assistant nurses fed the children with the support of the 201 
caregivers. Children were not allowed to take RUTF home and caregivers were advised not to 202 
feed children in the morning before coming to the site, except for children still on breast milk.  203 
No special recommendation was given for evening meal. Each study nurse assistant had less 204 
than 10 children to feed. The study nurse assistants were allocated to one study group for half 205 
of the study period before being changed to the other study group for the other half of the 206 
study.  207 
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Treatment protocol  208 
The nutrition and medical management of children in both study groups were similar and in 209 
general followed the DRC national guidelines with the exception of the following differences:  210 
The study used an admission criteria of MUAC<115mm or bilateral pitting edema in place of 211 
the national criteria of MUAC<110mm or bilateral pitting edema; the study used a discharge 212 
criteria of MUAC≥125mm and no edema for 15 consecutive days in place of the national 213 
criteria of MUAC ≥115mm and weight gain of 20% and no edema; children in the study were 214 
followed up daily at day care centers instead of weekly at the HC in the national guidelines 215 
and the study therapeutic food was given ad libitum instead of the fixed amount of 200 216 
kcal/kg/day in the national protocol (17). 217 
 218 
After admission into the study, all children received a 5-day course of amoxicillin and a single 219 
500 mg dose of mebendazole. All medications were directly administered to the child by the 220 
nurse at the day care sites in order to ensure that they were taken by the child. Vitamin A was 221 
not given because all the children had received a high dose of vitamin A of 200,000 IU within 222 
3 months of admission and because both RUTF contained substantial amount of vitamin A 223 
(table 1). For any episodes of infectious disease that occurred during follow up, any treatment 224 
prescribed was also directly administered by the nurses at the day-care site.  225 
Data collection and follow-up  226 
The study used a combination of specially trained study nurses as supervisors and study 227 
assistant nurses and nurses from participating health facilities as enumerators. Two weeks 228 
before the start of data collection, all enumerators received training on the diagnosis of SAM, 229 
its management and the follow up of cases.  They were also trained on data collection using 230 
an individual monitoring card that had been developed specifically for the study. Data 231 
collected on this form included administrative details, nutrition / medical history, physical 232 
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signs of disease, laboratory results at admission and during nutrition rehabilitation, nutrition, 233 
clinical signs and type of discharge. The nurses collected the data every morning during the 234 
period of study participation. A specially designed questionnaire book was used by study 235 
assistant nurses to collect additional information including actual RUTF intake, symptoms 236 
and physical signs of diseases observed by them during their surveillance of children at the 237 
feeding site and symptoms such as bloating, flatulence, abdominal pain or diarrhea that could 238 
have been related to RUTF intake.  Special forms were designed and used for the collection of 239 
specific data for BIA parameters and saliva samples for body composition assessment and 240 
blood samples for amino acid assessment. 241 
 242 
A trial week of the implementation of all protocols and routine data collection procedures 243 
preceded the start of the study in order to ensure the standardization of data collection and 244 
iron out any initial problems.  245 
Procedures  246 
Weight, height or length and MUAC were measured following WHO recommended 247 
procedures (18). Hemoglobin concentrations were measured in capillary blood, obtained from 248 
the fingertip, using a portable Hemoglobinometer (HemoCue® AB, Ängelholm, Sweden). 249 
The device was calibrated on a daily basis using a HemoCue Control Cuvette.  BIA 250 
parameters were determined using the manufacturer-recommended procedures for the hand-251 
foot Bodystat 1500 MDD system (Bodystat Inc, Douglas, United Kingdom), with 252 
accompanying measurements of weight and height. BIA was measured with the child in 253 
supine position with arms and legs slightly abducted from the trunk. The measurement started 254 
after 3 to 4 minutes in that position and was done with electrodes placed at the dorsal surfaces 255 
on wrist (between second and third metacarpals) and ankle (between second and third 256 
metatarsals) with the proximal and distal electrodes placed at a minimum of 5cm apart. The 257 
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impedance was measured at the frequencies of 50 KHz. The deuterium dilution technique 258 
(DDT) was undertaken in well-hydrated children with empty bladders.  Children were 259 
considered well-hydrated if they had no history of diarrhea for the past week, had no history 260 
of strenuous activity in the past 3 hours, had wet mouth and no history of recent sunken eyes 261 
and had no clinically noticeable edema. A single 3g dose of deuterium (children <10kg) or 6g 262 
(children 10 to 20 kg) was given in the morning after an overnight fast. The deuterium dose 263 
was pre-weighed on an electronic scale accurate to 0.01 g. Saliva samples were collected 264 
before the deuterium dose (baseline sample), 3 hours post ingestion (post-dose sample 1) and 265 
4 hours post ingestion (post-dose sample 2). The children were instructed to refrain from any 266 
food or fluid for at least 30 min before the post-dose saliva samples.  Saliva was collected by 267 
getting the children to chew on a ball of cotton wool to fill the ball with saliva.  The saliva 268 
was then sucked up out of the ball by a syringe. A sample collection was deemed successful if 269 
at least 2ml of saliva was collected. After collection, saliva samples were stored in a cool box 270 
for not more than 6 hours before being transferred to a freezer where they were stored at –271 
20ºC until shipment to the Nairobi based Kenya Medical Research Institute laboratory where 272 
they were also kept frozen until analysis. The deuterium enrichment in the saliva samples was 273 
measured by Fourier Transform Infared (FTIR) spectrometry(19). In the Deuterium Dilution 274 
technique, TBW was calculated using the value of the deuterium enrichment of the saliva, and 275 
the data were analyzed in association with the weight and height measured on the day of 276 
dosing. In the BIA analysis, TBW was calculated using a predictive equation developed using 277 
anthropometric data and BIA parameters collected in Ethiopian infants and children by one of 278 
the authors (20).  This equation was deemed by the authors to be more appropriate than other 279 
published equations. The FFM was derived from TBW derived using published age and 280 
gender specific constants for FFM hydration(21).  Human Immunodeficiency Virus (HIV) 281 
status was determined by Determine® and Unigold® using the serial approach as 282 
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recommended by the national guidelines. Plasma samples for amino acid analysis were 283 
obtained by venipuncture and collected in tubes with EDTA as an anticoagulant. The blood 284 
samples were stored immediately into Cubecooler ™ to maintain blood temperature at 4°C to 285 
prevent micro-hemolysis and degradation of amino acid by enzymes present in blood cells 286 
(22). Samples were transported within 4 hours after collection to a laboratory for 287 
centrifugation and deproteinization.   The blood was centrifuged at 3000g for 15 minutes at 288 
4°C to separate plasma (supernatant) from blood cells. For deproteinization, 100 µl of plasma 289 
were mixed with 200ul of 5% trichloro-acetic acid and the mixture was centrifuged at 290 
10,000g for 10min at 4°C.  The supernatant obtained from this second centrifugation 291 
(deproteinezed plasma) was then stored at−20°C until shipping in bulk to the Ajinomoto 292 
laboratory in Japan and was used for plasma amino acid measurement. The amino acid was 293 
measured by an L-8900 dedicated automated amino acid analyzer (Hitachi High-294 
Technologies, Tokyo, Japan) composed of a guard column and analytical column, following 295 
standard instruction from the device manufacturer (23).   296 
 297 
Food products used in the study 298 
Both study RUTFs were produced in Valid Nutrition factory in Malawi, an officially 299 
recognized UNICEF RUTF supplier. The factory has been supplying the Ministry of Health in 300 
Malawi since 2005 and has produced study foods for several published studies (11;24-30).  301 
Table 1 provides the composition of the two RUTFs obtained using the US Department of 302 
Agriculture food composition database, while table 2 compares their amino acid profiles 303 
obtained from actual laboratory analysis of the two products. The two types of RUTF were 304 
packed in similar sachets with different colored labels.  Based on our experiences from the 305 
Lusaka trial, we modified the micronutrient profile of the SMS-RUTF product used in this 306 
study, using a specially formulated vitamin and mineral premixes, and used dehulled soybean 307 
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and degermed maize.  The final product met the WHO 2007 recommendations for RUTF 308 
mineral and vitamin levels.  To compensate for the higher phytic acid (PA) content in the 309 
SMS-RUTF and improve the PA/iron and PA/Zinc molar ratio we increased the concentration 310 
of iron, zinc in the SMS-RUTF above the WHO recommended concentrations (31;32).  To 311 
improve Iron bio-availability in the SMS-RUTF we increased the Vitamin C content above 312 
the WHO recommendations.  We also increased the n-3 polyunsaturated fatty acid (PUFA) 313 
content and decreased the n-6 PUFA to obtain a n-6 PUFA: n-3 PUFA ratio less than 5(33).  314 
 315 
A pre-trial panel test demonstrated that the above changes did not affect consistency, color, 316 
odor or taste when compared to the product used in the Lusaka trial and we therefore did not 317 
re-run acceptability trial on the product. However, to ascertain and compare the acceptability 318 
of the two trial products particularly with regard to the difference in iron, lactose and non-319 
digestible oligosaccharides content, during the efficacy trial we collected data on abdominal 320 
pain, the occurrence of diarrhea, flatulence, abdominal distension and actual daily intake 321 
(34;35).  322 
Outcomes 323 
The primary outcomes of interest for this study were recovery rate, average daily weight gain 324 
and average length of stay (LOS).  Secondary outcomes included hemoglobin change, 325 
difference in, Fat Mass (FM), Body Fat Percentage (%BF) and Fat Mass Index (FMI), Fat 326 
Free Mass (FFM) and Fat Free Mass Index (FFMI) Phase Angle (PhA), and Illness Marker 327 
[IM].  The Plasma concentrations of 8 key amino acids at discharge were also studied.  328 
Sample size 329 
We calculated the sample size to demonstrate that SMS-RUTF was not inferior to P-RUTF 330 
for recovery rate, weight gain and LOS among children with SAM discharged as recovered 331 
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from the study. The sample sizes were calculated for a power of 80% and a level of statistical 332 
significance of 0.05. The margins of non-inferiority were 10% for recovery rate, 1.2 g kg-1 333 
day-1 for weight gain, and 14 days for LOS. These margins were defined based on the findings 334 
of our previous study conducted in Lusaka (11). For the recovery rate, the margin of non-335 
inferiority of 10% is fixed based the Lusaka SMS-RUTF study that suggested a recovery rate 336 
of over 80%  for the standard treatment (per protocol analysis) and the SPHERE standard 337 
requirement of minimum recovery of 75%. Based on data of the SMS-RUTF Lusaka study in 338 
which the weight gain rate and the 95% CI for the P-RUTF was 3.3 (2.8-3.7), the margin of 339 
non-inferiority was fixed at 1.2g/kg/day. The non-inferiority margin for the length of stay of 340 
14 days was fixed based on the cost of the program and the fact that follow ups of these 341 
children are either weekly or fortnightly. We estimated that a difference of 14 days will be 342 
associated with a significant increase in cost of treatment in a context of restricted budget. As 343 
the findings of our earlier study in Lusaka indicated potentially different responses between 344 
younger and older children, sample sizes were calculated separately for children 6-23 months 345 
of age and for those aged 24 - 59 months (11). The sample size was calculated using the web-346 
based software “Power”(36).  A total of 448 SAM children aged 6-24 months and 316 SAM 347 
children 24 to 59 months were required to be 80% sure that the lower limit of a one-sided 348 
95% confidence interval (CI) would be above the set limits of non-inferiority (37;38). Due to 349 
budgetary constraints convenience samples were chosen for the secondary objectives. These 350 
were 200 SAM children (100 per study group) and 20 age and sex matched community-351 
controls for hemoglobin; 60 SAM children (30 per study group) and 60 age and sex matched 352 
community-controls for body composition by DDT; 200 SAM children (100 per study group) 353 
for body composition using BIA and 60 SAM children and 25 age and sex matched controls 354 
for the determination of the distribution of free amino acids concentrations.  355 
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Data management, definitions and analysis  356 
Data management  357 
Throughout the study, the data quality manager and the principal investigator conducted field 358 
supervisions during which they spot-checked the quality of anthropometric measurements, 359 
edema diagnosis, individual data collection forms and the study questionnaire books filling. 360 
All the individual data collection forms were checked again for accuracy and completeness at 361 
the time of child discharge from the study.  The verified forms were then collected for data 362 
entry. Data were double entered by two enumerators into a customized Epidata database 363 
prepared for this study (39). Quality of data entry was monitored by the supervisors who 364 
cross-checked a random selection of 10% the records.  Given that independent teams 365 
regularly verified anthropometry measurements, no value was excluded. Cleaned data were 366 
exported to stata-11 (40) for analysis.  367 
Definitions  368 
Recovery rates were defined as the percentage of children who were discharged as recovered 369 
from the study divided by the total number of children who exited the study.  The total of 370 
children who exited the study included all those who defaulted, died or were discharged as 371 
non-recovered after either meeting the non-recovered criteria (90 days in the program) or at 372 
the closure of the program. A child was considered to have defaulted if he/she was absent for 373 
five consecutive daily visits and if he/she refused to return after two community workers 374 
home visits.  375 
Rates of weight gain were calculated by dividing the weight gain expressed in grams (weight 376 
at exit –weight at admission) by the weight at admission (in kilograms) and the LOS (in 377 
days).  378 
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Average weight gains were measured as the mean of the individual weight gains expressed in 379 
g/kg/day.  The average LOS was calculated by dividing the sum of individuals LOS by the 380 
total number of children included in the numerator calculation.  381 
The hemoglobin change was the difference in blood hemoglobin concentrations between 382 
admission and discharge from the study in all children with measurements taken at both 383 
points.  384 
FM in both the Deuterium Dilution Technique and BIA was calculated as the difference 385 
between body weight (BW) and FFM. %BF was obtained by the equation 386 
%BF=(FM*100)/BW. The FFMI (fat-free mass/height2) and FMI (fat mass/height2) were 387 
obtained by dividing FFM and FM expressed in kilograms, by the square of the height 388 
expressed in meters. Resistance (R) and reactance (Xc) were adjusted for height by dividing 389 
the observed values of these BIA parameters by the height of the child (41). PhA and IM were 390 
calculated directly by the BIA Bodystat MDD machine.   391 
Analysis 392 
Means and standard deviations (SD), medians and interquartile ranges (IQR) or proportions 393 
and 95% Confidence intervals (95%CI) were used to describe the admission and exit 394 
parameters, as appropriate. Means were compared using t-test, medians using the Mantel–395 
Haenszel test and proportions using the Student’s chi-squared test.  Differences in the 396 
estimated marginal mean between the treatment groups along with a bootstrapped 95% CI 397 
was estimated to draw inference on non-inferiority.  398 
For the primary outcomes, in accordance with recommendations for analyzing and reporting 399 
equivalence and non-inferiority studies, both Intention-To-Treat (ITT) and Per-Protocol (PP) 400 
analyses were performed and the confidence intervals were used to interpret any differences 401 
(42;43). The ITT analyses included all children enrolled in the study.  The PP analyses for 402 
recovery rates included all children discharged out of the program as recovered, dead or non-403 
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recovered but excluded children who defaulted or who transferred out of the program and 404 
were lost to follow-up after inpatient transfer.  The PP analyses for weight gains included only 405 
the children who were discharged as recovered. Logistic regression was used to test for 406 
interactions between the recovery rate and other variables. For the secondary outcomes, 407 
means were compared using Student's two-tailed t test and median were compared using 408 
Kruskall-Wallis. Bonferroni correction was applied in case of multiple comparisons of means 409 
or medians and level of p-value for reaching statistical significance adjusted accordingly. 410 
Multiple linear regression was used to model effect of SMS-RUTF on hemoglobin increase.  411 
Ethical considerations 412 
Permission to conduct the study was obtained from the Ethics Committee of the Catholic 413 
University of Bukavu (DRC) and the study was registered prior to staring data collection in 414 
the Pan African Clinical Trial Registry (PACTR201303000475166). At the time of 415 
admission, each child’s parent or carer was informed about the nature and purpose of the 416 
study and asked for their verbal and written consent for their child to be included and for their 417 
medical information to be used for research purposes. When parents or carer withheld consent 418 
for participation, children were referred to one of the four non-participating clinics providing 419 
care for SAM in Miti-Murhesa HZ. These clinics were supported by the DRC Government 420 
and UNICEF. They used Standard P-RUTF procured from France.  The other benefit of 421 
participating children included free medical care for any episode of disease during the follow 422 
up and one porridge meal per day given to carers when looking after their children at the 423 
feeding site. 424 
A data safety monitoring board was assigned to perform an ongoing review of study outcomes 425 
based on data extracted by themselves from either the study subject’s files or the study 426 
database during the bi-monthly visit. The findings served only to decide if the study should be 427 
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ended due to an indication of serious side effects. No serious side effects were detected and 428 
no reasons for interrupted the study identified. 429 
 430 
Results 431 
Enrolment and movement of subjects from preliminary screening to data analysis for the 432 
whole cohort and by age category are shown in Figure 1.  Between March 2013 and February 433 
2014, a total of 924 eligible children were screened, of whom 886 were randomized to either 434 
SMS-RUTF (n = 445) or P-RUTF (n = 441) study groups.  Thirty-eight eligible children were 435 
excluded prior to randomization and another 11 children (6 in the SMS-RUTF group and 5 in 436 
the P-RUTF group) withdrew from the study after only one day of attendance after they 437 
realized that they could not fulfil the daily attendance requirement. This was classified as 438 
“after first day refusal”. 439 
Baseline characteristics of children included in the ITT analyses for each study group are 440 
shown in table 3.  Marasmus was the dominant form of SAM among children enrolled into 441 
the study and there was no significant difference between groups at baseline for the 442 
parameters considered in either of the two age categories.   443 
Program outcomes: recovery, mortality, defaulter and non-response  444 
In children between 24 – 59 months of age the results of the ITT analysis showed that both 445 
products met international minimum standards.  In the SMS-RUTF group, recovery, 446 
mortality, defaulter and non-response rates were 88.3% (204/231), 1.7% (4/231), 7.8% 447 
(18/231) and 2.2% (5/231), respectively. In the P-RUTF group the results were 90.3% 448 
(214/237), 0.4% (1/237), 7.6% (18/237) and 1.7% (4/237), respectively.   449 
 450 
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By contrast, in children 6 - 23 months of age the ITT analysis demonstrated that international 451 
minimum standards were met for the P-RUTF group but not for the SMS-RUTF group.  In 452 
this age category the SMS-RUTF group’s recovery, mortality, defaulter and non-response 453 
rates were 54.3% (113/208), 3.4% (7/208), 24.5% (51/208) and 17.8%(37/208) compared to 454 
75.1% (148/197), 1.0% (2/197), 15.7% (31/197) and 8.1% (16/197) in the P-RUTF group.   455 
Primary outcomes 456 
Both ITT and PP analyses showed that in children aged 24 -59 months the recovery rate 457 
(predefine non-inferiority margin Δ = 10%) of the SMS-RUTF group was not inferior to the 458 
recovery rate of the P-RUTF group.  By contrast, in children aged 6 - 23 months the recovery 459 
rate in the SMS-RUTF group was inferior to the recovery rate in the P-RUTF group (figures 460 
2 and 3). For weight gain, the PP analysis for weight gain in children who were discharged as 461 
recovered showed that the SMS-RUTF group was not inferior to P-RUTF group (predefined 462 
non-inferiority margin Δ = 1.2 g/kg/day) in either age category (Figure 4).  SMS-RUTF was 463 
not inferior to P-RUTF in terms of LOS (predefined non-inferiority margin of Δ =14 days) 464 
both in ITT analysis and among recovered children (figure 5). 465 
 466 
Results of the secondary outcomes 467 
Hemoglobin 468 
The unadjusted analysis showed no difference in the means hemoglobin changes between the 469 
two RUTF groups for all children evaluated [+1.04(0.79-1.30) g/dl for SMS-RUTF group 470 
versus +1.06(0.84,1.28) g/dl a difference of 0.02(-0.31, 0.35) g/dl; p=0.921)] and for those 471 
discharged as recovered [+1.23(0.95-1.50) g/dl for SMS-RUTF group versus +1.19(0.90-472 
1.47) g/dl, a difference of 0.04(-0.35, 0.44) g/dl; p=0.837)]. The difference in the proportion 473 
of anemic children (hemoglobin<11.0 g/dl) in children discharged as recovered was also not 474 
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statistically significant [19/72=26.39% for SMS-RUTF group and 24/80=30.0%, a difference 475 
of -3.61(-17.91, 10.69) %; p=0.622)]. The study was underpowered to reach level of statistical 476 
significance for differences observed. Linear regression analysis adjusting for age, gender, 477 
hemoglobin at admission, daily energy intake from RUTF, LOS in study and growth velocity 478 
(supplemental table 1 for full results of the linear regression) indicated that treatment with 479 
SMS-RUTF was associated with a statistically significant greater increase in hemoglobin of 480 
0.670(0.420-0.921)g dl-1 when compared to children treated using P-RUTF (p<0.001). The 481 
difference of 0.743(0.427–1.059) g dl-1 when only children discharged as recovered were 482 
included in the analysis was also significant (p<0.001).  483 
Amino acids 484 
At admission the overnight-fasting plasma concentrations of the tested free amino acids did 485 
not differ according to the RUTF group.  Comparison with community controls children 486 
without acute malnutrition showed that malnourished children enrolled in both groups had 487 
significantly reduced concentration of several of these AAs (table 4).  Nutrition rehabilitation 488 
with both SMS-RUTF and P-RUTF resulted in the replenishment of all the AAs tested by the 489 
time of discharge, except for methionine (table 4). Stratified analyses showed that at the time 490 
of discharge, in children aged 6-23 months the deficit was corrected for all the tested AAs, 491 
whereas in older children, plasma concentration of both methionine and phenylalanine 492 
remained lower than the community controls at the time of discharge (Supplemental tables 2 493 
and 3). 494 
Body composition 495 
For children discharged as recovered, there were no differences at discharge between RUTF 496 
groups or between the RUTF groups and the community controls in fat mass or fat mass index 497 
in the DDT sub-study (table 5).  By contrast, two by two comparisons of FFM indicated that 498 
 The American Journal of Clinical Nutrition AJCN/2015/119537 Version 2
26 
 
 
 
children after treatment with either of the two RUTFs had significantly lower levels of FFM 499 
than the community controls (Table 5), but this difference disappeared after adjusting for 500 
height.  501 
The comparison of the BIA parameters between the sub-samples of SAM children tested at 502 
admission and re-tested at the time of reaching MUAC 125mm, showed no significant 503 
differences between children in the two intervention groups (Supplemental table 4). 504 
However, at discharge from the study, children in the SMS-RUTF group had higher IM and 505 
lower FFMI, PhA and Xc/H compared to children in the P-RUTF group (table 6). The SMS-506 
RUTF BIA subgroup also tended to have greater height than the P-RUTF BIA subgroup. 507 
Technical challenges (lack of cooperation of children at the beginning of the nutrition 508 
rehabilitation or presence of edema) limited the number of children with successful BIA 509 
measurement at admission (43 surveyed out of the 200 selected) and at the time of reaching 510 
12.5 cm of MUAC (57 children surveyed out of 200 selected) reducing the statistical power of 511 
the BIA analysis at these time points. At discharge, the number of children surveyed was 164 512 
children out of the 200 selected). 513 
Linear growth 514 
Overall in this study there was no clinically relevant catch-up in height for age during 515 
treatment and no significant differences in linear growth between the RUTF groups.  The 516 
severity of stunting in children aged 6 - 23 months at enrolment increased very slightly over 517 
the study period, whilst in children aged between 24 - 59 months there was a small but 518 
clinically insignificant improvement.  Within group analysis showed that the daily increments 519 
length gain were not different between children discharged as recovered and children 520 
discharged as not-recovered (Supplemental table 5). 521 
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RUTF intake, acceptability and tolerance  522 
RUTF intake 523 
The intake of RUTF was higher for children in the P-RUTF group.  For children aged 6 - 24 524 
months the mean(SD) daily intake was 183.2 (76.3) g/day for SMS-RUTF versus 207.8 (76.4) 525 
g/day for P-RUTF, a difference(95%CI) of = -24.6 (-39.6, -9.6) g/day; p=0.001.  For children 526 
aged 24 – 59 months the mean(SD) daily intake was 243.8 (86.8) g/day for SMS-RUTF 527 
versus 272.7 (77.9) g/day for P-RUTF, a difference(95%CI)  of = -28.9(-43.94,-13.9) g/day; 528 
p<0.001 (Supplemental table 6)   529 
Energy intake was significantly higher in children aged 24-59 month receiving P-RUTF 530 
compared to the same age group receiving SMS-RUTF [142.7 (50.8) kcal/kg/day for SMS-531 
RUTF group versus 157.2 (51.9) kcal/kg/day in the P-RUTF group, a difference of -18.63 (-532 
27.65, -9.51); p<0.001.  The differences in energy intakes in the younger age group [149.5 533 
(82.9) kcal/kg/day for SMS-RUTF group versus 165.7 (58. 7) kcal/kg/day for P-RUTF a 534 
difference of -16.2(-30. 4, -2.0) kcal/kg/day was also significant; p=0.026.  Within each 535 
RUTF group and each age categories, the daily energy intake did not differ between those 536 
who recovered and the non-respondent discharged as non-recovered (data not shown). 537 
RUTF acceptability 538 
The data on RUTF acceptability suggested that the only difference between the two RUTF 539 
products was that fewer children below 24 months experienced flatulence on the SMS-RUTF 540 
(supplementary table 6).  Among those who defaulted, a dislike of the RUTF was reported in 541 
19.2% (14/73) of the SMS-RUTF group versus 13.3% (6.45) in the P-RUTF group; p=0.411.  542 
Among the same group side effects related to RUTF intake were 2.74% (2/73) in the SMS-543 
RUTF group versus 2.22% (2/45) in the P-RUTF group; p=0.862.  544 
 545 
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Discussion 546 
Children with SAM need safe, palatable foods with energy, protein, fat, minerals and vitamins 547 
tailored to their needs for restoration of normal body functions and catch up growth(32). 548 
Providing P-RUTF tailored to body weight has been shown to successfully support catch-up 549 
growth(2;44), but, P-RUTF is expensive and the high cost affects the coverage and the 550 
sustainability of CMAM programs. Almost half of the cost of the P-RUTF is due to milk 551 
powder that constitutes 25% to 30% of the content of P-RUTF and removing the milk from 552 
RUTF has the potential to substantially reduce the cost of such products. Although predicting 553 
saving accurately without undertaking actual commercial scale trials is difficult, our analysis 554 
in Malawi, where the study foods were produced, suggests a 15% saving on finished product 555 
cost. However, the saving is likely to vary from one year to another according to milk price in 556 
local and global market and to the country of production.  557 
 558 
This study has yielded important information regarding the efficacy of the no milk SMS-559 
RUTF. It has confirmed that SMS-RUTF is not inferior to P-RUTF in children ≥24 months of 560 
age with respect to recovery rate, weight gain and length of stay and therefore can be used as 561 
an alternative to P-RUTF.   Importantly the study has showed that treatment with both SMS 562 
and P-RUTFs corrected amino acid deficiencies to a similar extent and both RUTFs were not 563 
associated with excess of fat deposition.  The BIA sub-study, confirmed substantial increases 564 
in the FFMI in both groups bringing them back to a par with the community controls.  In the 565 
SMS-RUTF group the increase in FFMI was slightly less than in the P-RUTF corresponding 566 
to the greater increases in length seen in this group.  This minor difference in FFMI was 567 
associated by a small difference that is unlikely to have any clinical importance in the markers 568 
of FFM quality (phase angle, IM) that were also lower in the SMS-RUTF group, the greater 569 
increase in hemoglobin produced by SMS-RUTF compared to P-RUTF also shows that it is 570 
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possible to improve the efficacy of RUTF formulations in correcting anemia.  At the same 571 
time, the study has provided evidence that children aged <24 months don’t respond as well to 572 
SMS-RUTF and that P-RUTF should continue to be used for this age group until a cheaper 573 
alternative is developed. 574 
.   575 
The need of animal source food, especially of cow milk products, in food for management of 576 
acute malnutrition including moderate and severe acute malnutrition is still subject of an on-577 
going debate (45-49). Several properties of milk including the high quality of the proteins, the 578 
presence of bioactive factors, the minerals profile and the high lactose content are given as 579 
reasons for the obligatory inclusion of a certain amount of milk in RUTF (49). As a result the 580 
current UN guidelines specify that more than 50% of the protein in RUTF should be from an 581 
animal source.  However, several studies from industrialized countries have shown that in fast 582 
growing infants, soya can successfully replace cow milk when there is medical or socio-583 
cultural contraindication to milk (50).  Similarly, a study published in 1996 showed that the 584 
effectiveness of soya milk and cow milk were similar in nutrition rehabilitation of SAM (51) 585 
and we have previously demonstrated that it is possible to achieve the recommended nutrient 586 
profile for RUTF without the inclusion of milk (52).  The present study confirms our earlier 587 
findings from Zambia that an SMS-RUTF containing no animal source protein is as effective 588 
as P-RUTF in treating SAM in children 24 months or older(11).  This finding has important 589 
practical implications, indicating that the cost of the CMAM programs can safely be reduced 590 
by using SMS-RUTF in all children above the age of two and restricting the more expensive 591 
P-RUTF for use in children less than 2 years of age.  592 
 593 
The reasons for the inferior response to the milk-free RUTF in children less than 2 years are 594 
not clear.  They could be related to one or more factors including differences in 595 
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energy/nutrient intake, in protein quality, in the prevalence of lactose intolerance, the bio-596 
availability of essential nutrients or physiological responses between the two age groups.  We 597 
believe that differences in energy intake are unlikely to be important.  In a study of adults 598 
treated with a Chickpea Sesame RUTF that contained no milk or other animal source protein, 599 
there was an excellent correlation between RUTF intake, weight gain and FFM change(53).  600 
By contrast, in the present study there was no significant difference of daily intake between 601 
the age categories indicating that the poorer response was not the result of any reduction in 602 
the intake of energy.  In children <2 years of age who did not recover the average RUTF 603 
intake was 133 kcal/kg/day and this energy intake, although lower than the recommended 604 
intake of 200 kcal/kg/day , should have been sufficient to cover basal metabolic requirements 605 
and allow for some growth and recovery.  In addition all these children were still breastfed 606 
and it is likely that breast milk further contributed to their energy intake.  The contribution of 607 
breast milk to their nutritional intake is however unknown as although evidence suggests that 608 
RUF used for the prevention of malnutrition does not reduce breast milk intake, there is no 609 
data on whether this is true when RUTF is prescribed in much larger amount for 610 
treatment(54).  611 
 612 
Differences in protein quality between SMS-RUTF and P-RUTFs combined with a greater 613 
requirement for certain amino acids in young children cannot be ruled out as a cause of the 614 
inferior response to the milk-free RUTF in children less than 2 years. SMS-RUTF had a lower 615 
content of tyrosine, methionine and proline than the P-RUTF.  The mean daily SMS-RUTF 616 
intake in children discharge as “non-recovered” corresponded to a daily intake of 121 617 
mg/kg/day of tyrosine and 52 mg/kg/day methionine.  These intakes are greater than the 99 618 
mg/kg/day of tyrosine that Badaloo et al. estimated was needed to support catch-up growth of 619 
g/kg/day (55), above the 38 mg/kg/day of methionine required by formula fed infants who 620 
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grow at more than10 g/kg/day (56). The increased plasma levels of free amino acids between 621 
admission and discharge and compared to those seen in community controls indicates that the 622 
two RUTFs supplied sufficient quantity of these amino acids. However, we did not measure 623 
all the amino acids and the sample size did not allow testing a sufficient number of non-624 
recovered children. Thus, future research should still assess possible contribution of some key 625 
amino acids in the poor physical growth in children below 24 months recovering from SAM. 626 
A decreased bio-availability of essential nutrients is another possible cause for the inferior 627 
response to the milk-free RUTF in the younger children.  Phytic acid is a common plant 628 
storage compound that binds divalent metallic ions preventing their absorption in the small 629 
intestine that is not present in animal source foods.  It is therefore theoretically possible that 630 
the switch from milk to the grains and legumes could have increased the phytic acid content 631 
of the SMS-RUTF decreasing the bio-availability of iron and zinc.  We believe that this is 632 
explanation is however unlikely.  A recent laboratory analysis of different P-RUTFs found 633 
huge variations in the phytic acid levels, that ranged from 1015mg/100g for P-RUTF 634 
produced in Europe down to 371 mg/100g for P-RUTF manufactured in African countries 635 
(57). The iron content of 10-14 mg/100g in the P-RUTF combined with these amounts of 636 
phytic acid give phytic acid/iron ratios between 7– 13, far higher than the recommended 637 
upper limit ratio of <1(58).  By contrast, the production of SMS-RUTF included specific 638 
measures to reduce phytic acid and to increase the content of iron.  This resulted in a phytic 639 
acid acid/iron ratio of 0.8.  Based on evidence that increasing vitamin C improves absorption 640 
of iron (59;60), the vitamin C content of the SMS was also increased to enhance the iron 641 
bioavailability.  The greater increase in hemoglobin amongst children receiving SMS-RUTF 642 
suggests that these measures were effective in increasing iron absorption.  The SMS-RUTF 643 
also included more zinc compared to P-RUTF in order to bring the phytic acid/zinc ratios 644 
towards international recommendations (see table 1).  Specific iron and zinc absorption 645 
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studies should be done to confirm that the strategy used to improve bioavailability of these 646 
minerals was sufficient.  647 
 648 
Several studies have reported that tolerance of lactose declines naturally with age with the 649 
prevalence of lactose intolerance increases sharply after the cessation breastfeeding at round 650 
24 months of age (61;62). Indeed, post weaning genetically programmed and irreversible 651 
reduction of lactase activity has been described worldwide (63).  Thus increasing lactose 652 
intolerance in the older children could explain the differences seen with the benefit of the 653 
growth promoting nutrients present in milk increasingly counterbalanced by the negative 654 
effect of lactose intolerance in the older children.  However, as the response to treatment in 655 
both the study arms was superior amongst children ≥24 months this explanation is unlikely. , 656 
a conclusion supported by the fact that several studies have previously reported similar 657 
growth pattern in lactose intolerant children given lactose free dairy products compared to 658 
lactose intolerant children given dairy products containing lactose (61;62).    659 
 660 
Differences in the pathophysiology of SAM between the two age groups is likely to be 661 
important in both the inferior response in the treatment of SAM and also the different the 662 
linear growth response of the younger and older children that we observed.  In this study, the 663 
length for age in children below 24 months of age continued to decline during nutrition 664 
treatment whereas in the older children some linear growth catch up was observed during 665 
treatment.  This suggest that the nutrient requirement for rehabilitation may not be the same 666 
for children off different ages and it is likely that similar physiological differences are also 667 
important reasons behind the inferior response to the milk-free RUTF in the younger children.  668 
These findings highlight the need to enhance our understanding of the differences between 669 
younger and older SAM children, including differences in biochemical parameters, in nutrient 670 
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requirements, body composition at different stage of acute malnutrition as well as the precise 671 
composition of weight gain at different time of the recovery process. Such information is 672 
likely to facilitate the adjustment of RUTF composition with the aim of developing a product 673 
capable of reversing both wasting and stunting, especially in children below 24 months.  674 
 675 
In this study there was a significantly greater increase in hemoglobin with no evidence of 676 
increased morbidity using an RUTF with an iron content approximately four times greater 677 
than that currently recommended.  This suggests a need to revise the current recommendation 678 
and increase iron density in RUTF.  Historically fears that iron might induce the formation of 679 
free radicals that could not be detoxified in children with SAM meant that the iron content of 680 
RUTF was kept low(64;65).  More recently new concerns related to the promotion of 681 
pathogenic bacteria in the gut that some studies have attributed to iron fortified food (66;67) 682 
have served to keep the iron content of RUTF down(68-70). However, other studies have 683 
shown that increasing iron levels in nutritional supplements has positive effects on growth 684 
(71) and on hemoglobin (72) as well as indicating that iron can be safely prescribed to 685 
children recovering from severe malaria, a condition that in the past has been associated with 686 
very high post-discharge mortality (73;74).  An unpublished study conducted in Senegal also 687 
showed that during the treatment of SAM using P-RUTF with the current recommended iron 688 
density hemoglobin went up by 0.17 g/dl compared to an increase of 0.83 g/dl in those 689 
receiving F100 therapeutic milk fortified with iron to provide 3mg/kg/ day(75).  It is 690 
important to note that even at the increased iron dosage used in the SMS-RUTF there were 691 
still a high proportion of anemic children at discharge and it is likely that any solution to the 692 
problems of anemia in SAM will require a mechanism to increase iron intake for several 693 
months post discharge. To the best of our knowledge, this is the first study using the reference 694 
two compartments model technique for the determination of body composition (DDT 695 
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approach), showing that the use of RUTF for nutrition rehabilitation of SAM children is not 696 
associated with excess deposition of fat. All previous studies that evaluated this issue were 697 
done in program using milk based diet (76-78). These studies showed that nutrition therapy 698 
with appropriately fortified milk diet is not associated with excesses in fat mass deposition 699 
(76-78). However, despite these publications there has been a continued debate around the 700 
possible association between rapid weight catch up growth observed during nutrition 701 
rehabilitation of SAM and higher amounts of body fat deposition and insufficient repletion of 702 
muscle and visceral proteins(78-82). Our findings show no excess fat deposition either with 703 
SMS-RUTF or with P-RUTF when compared to community controls and that at the time of 704 
discharge the absolute fat mass in children who had met anthropometric discharge criteria was 705 
similar to community controls.  These results confirm the findings of a recently published 706 
study conducted in Kampala (Uganda) that, through the use of serum leptin level as proxy 707 
biomarker of fat reserves, demonstrated that fat replenishment is completed first and early 708 
during nutrition rehabilitation, before the anthropometric discharge criteria are met (83). 709 
 710 
Our results also show that at the time these children meet anthropometric criteria for recovery 711 
they still have deficits of FFM when compared to the community controls.  This indicates that 712 
at current best practice SAM treatment regimens combined with the use of the internationally 713 
accepted discharge criteria are not necessarily sufficient to re-establish FFM.  This important 714 
finding provides a rationale for the persisting increased risk of death in children who are 715 
treated and attain “anthropometric cure” in tertiary hospitals after admission at an advanced 716 
stage of wasting and metabolic adaptation (84;85).  It also maybe helps to explain the much 717 
lower long term mortality risk post discharge of those admitted to community based programs 718 
at an earlier stage of the progression of SAM.(84).  719 
 720 
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In this study the fat mass and the FFMI of children who recovered was comparable to that of 721 
the community controls, suggesting that the differences in the absolute amounts of FFM could 722 
be explained by differences in height. It is therefore possible the residual increased risk of 723 
mortality post discharge after the treatment of SAM may be related to the degree of 724 
stunting(86).  The close inter-connections between acute and chronic malnutrition combined 725 
with the relatively limited impact of short duration treatment with RUTF on stunting supports 726 
the need to investigate integrated approaches towards acute and chronic malnutrition (87-89). 727 
Such approaches that combine intensive initial nutrition rehabilitation to correct 728 
weight/muscle deficit and prolonged nutrition support to re-establish FFM and sustain 729 
recovery of linear deficit should be developed and their effectiveness in preventing relapse 730 
and promoting linear growth and FFM catch ups assessed.  731 
 732 
BIA analysis gave similar results to DDT regarding change in body fat, Fat Free mass and Fat 733 
Free mass index. In addition the BIA analysis identified significant differences in cellular 734 
membranes function indicators such as phase angle and wellness marker between children 735 
treated with SMS-RUTF and those treated with P-RUTF. The clinical significance of the 736 
observed differences is unknown and need further investigations but many studies have 737 
demonstrated that Phase angle is an independent predictor of diseases and death in both 738 
children and adults (90-94).  739 
 740 
This study was conducted in a setting where all the ingredients are already commonly used in 741 
the preparation of porridge for complementary feeding. Despite that, our findings can be 742 
generalized as soya and maize have been used in food distributed during humanitarian crises 743 
worldwide and existing evidence shows that the standard RUTFs is effective in children 6 to 744 
59 months of age suffering from SAM of all continents even where peanut paste is not 745 
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commonly used in feeding infant and young children.  Also, we enrolled children using 746 
criteria universally used for enrollment in CMAM programs.  However, our findings should 747 
be interpreting taking into account some limitations. The main limitation is that we were 748 
unable to measure the total daily nutritional intake and measured instead only RUTF intake. 749 
Measuring total daily intake would have allowed us to better distinguish the effect of product 750 
composition on satiety on the response observed in both under twos and over twos. Although 751 
we doubt that the intake from home food or breast milk influenced the recovery, we were 752 
unable to exclude it definitively.  The second limitation is that we were unable to include 753 
sufficient number of children who did not recover into the sub-studies evaluating the 754 
evolution of amino acid profile or assessing body composition to allows determine if 755 
differences in food quality such us in amino acid profile contributed to the differences 756 
observed. 757 
 758 
In conclusion, the present study has demonstrated that SMS-RUTF can be used to treat SAM 759 
in children ≥24 months of age and that the iron content in RUTF should be increased.  The 760 
lower cost of manufacture of SMS-RUTF and its reliance on locally grown ingredients would 761 
reduce the costs of CMAM programs and facilitate the production of RUTF in countries with 762 
a high burden of SAM, especially because we have placed this recipe in the public domain 763 
and put in place mechanisms  preventing any entity from blocking access to it. The additional 764 
iron would increase the efficacy of the product in the treatment of anemia associated with 765 
SAM.    766 
The study has also shown that there is a need for two products with different composition to 767 
treat SAM.  One for children under 2 years that ideally should also be optimized to promote a 768 
reversal of stunting and one for the older children that should be formulated to maintain 769 
efficacy but reduce costs. Cost-effectiveness analyses and the assessment of the impact on 770 
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program logistic are needed to guide the final decision. More research is required to identify 771 
the reasons for the lower recovery rate with SMS-RUTF in younger children. Hypotheses to 772 
be explored include higher satiety with SMS-RUTF, lower breast milk intake, sub-optimal 773 
absorption of some key micronutrients and difference in key amino acids.  More research in 774 
also needed on products that better address stunting in this younger age group. 775 
  776 
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Table 1: Ingredients and nutrients of the study foods 
Ingredients/Nutrients SMS-RUTF1 P-RUTF2 UN specifications3 
Ingredients    
Soybean , dehulled                    (g/100g) 38.6 0.0  
Maize, degerminated                (g/100g) 4.0 0.0  
Sorghum, white, whole grain   (g/100g) 10.0 0.0  
Dried Skim Milk(g/100g) 0.0 25.0  
Sugar                                         (g/100g) 16.7 27.4  
Peanut paste                               (g/100g) 0.0 26.0  
Palm Oil                                     (g/100g) 21.6 20.0  
Linseed oil                                  (g/100g) 2.1 0.0  
Palm stearin                                (g/100g) 4.0 0.0  
Vitamin and minerals Premix     (g/100g) 3.0 1.6  
Nutrients    
Energy                                    (kcal/100g) 553 530 520-550 
Protein/Energy ratio                     (%) 11.9 12 10-12 
Fat/Energy ratio                            (%) 59.1 56.0 45-60 
Omega-6/Energy ratio                  (%) 12.3  3-10 
Omega-3/Energy ratio                  (%)                3.1  0.3-2.5 
Omega-6/Omega-3 ratio 4.0  5-9 
Vitamin A                              (µg/100g) 1000 910 810-1100 
Vitamin C                              (mg/100g) 329 53 ≥50 
Vitamin D                              (µg/100g) 14 16 15-20 
Vitamin E                               (mg/100g) 40.7 20 ≥20 
Thiamin (Vitamin B1)          (mg/100g) 1.4 0.6 ≥0.5 
Riboflavin (Vitamin B2)       (mg/100g) 1.9 1.8 ≥1.6 
Niacin (Vitamin B3)              (mg/100g) 19 5.3 ≥5 
Pantothenic acid (Vitamin B5)(mg/100g) 8.3 3.1 ≥3 
Pyridoxine (Vitamin B6)        (mg/100g) 1.4 0.6 ≥0.6 
Biotin (Vitamin B7)                 (µg/100g) 56 65 ≥60 
Folates  (Vitamin B9)              (µg/100g) 370 210 ≥200 
Cobalamin (Vitamin B12)       (µg/100g) 4.3 1.8 ≥1.6 
Vitamin K                                (µg/100g) 14 21 15-30 
Calcium                                   (mg/100g) 437.8 315 300-600 
Phosphorus                              (mg/100g) 446.0 370 300-600 
Magnesium                              (mg/100g) 74 86 60-140 
Potassium                                (mg/100g) 1155.8 1140 1100-1400 
Copper                                     (mg/100g) 0.9 1.7 1.4-1.8 
Iodine                                      (µg/100g) 417 100 70-140 
Iron                                          (mg/100g) 43.8 12 10-14 
Zinc                                         (mg/100g) 18.5 11.1 11-14 
Anti-nutrients     
Phytic acid                               (mg/100g) 420 255 <100 
Phytic acid/Zinc ratio 2.0 2.2 <15 
Phytic acid/Iron ratio 0.8 1.9 <1 
1SMS-RUTF=Soya-Maize-Sorghum Based Ready-To-Use Therapeutic Food; 2P-RUTF= 
Peanut paste based Ready-To-Use Therapeutic Food; 3Obtained from references 4, 15 and 16. 
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Table 2: Comparison of the amino acid profile of the study Ready-To-Use Therapeutic foods obtained by laboratory analysis 
Amino acid (g/100g) SMS-RUTF
2
 
P-RUTF
3
 
SMS-RUTF/P-RUTF ratio Adjusted
1
 SMS-RUTF/P-RUTF ratio  
Cystine 0.31 0.18 1.72 1.54 
Methionine 0.22 0.25 0.88 0.78 
Aspartic Acid 1.95 1.39 1.40 1.24 
Threonine 0.70 0.54 1.30 1.16 
Serine 0.94 0.82 1.15 1.02 
Glutamic Acid 3.24 3.01 1.08 0.96 
Glycine 0.74 0.53 1.40 1.25 
Alanine 0.81 0.52 1.56 1.37 
Valine 0.77 0.71 1.08 0.96 
Isoleucine 0.77 0.60 1.28 1.14 
Leucine 1.41 1.20 1.12 1.03 
Tyrosine 0.51 0.56 0.91 0.81 
Phenylalanine 0.86 0.72 1.19 1.06 
Lysine 1.05 0.93 1.30 1.01 
Histidine  0.46 0.37 1.24 1.11 
Arginine 1.21 1.01 1.20 1.08 
Proline 0.94 1.07 0.88 0.79 
Tryptophan 0.24 0.20 1.20 1.07 
1adjusted by using the true protein digestibility for soybean flour, sorghum flour and corn flour for the SMS-RUTF 
and Milk and peanut butter for the P-RUTF; 2SMS-RUTF=Soya-Maize-Sorghum Based Ready-To-Use Therapeutic 
Food; 3P-RUTF= Peanut paste based Ready-To-Use Therapeutic Food; 
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Table 3: Baseline characteristics for children included in the Intention-To-Treat analysis 
Criteria 6-23 months 24-59 months 
  SMS-RUTF
1
 
P-RUTF
2
 
SMS-RUTF
1
 
P-RUTF
2
 
n 208 197 231 237 
Socio-demographic parameters 
Male, n(%) 110(52.9) 93(47.2) 115(49.8) 108(45.6) 
Age (months), Mean(SD) 15.8(5.3) 15.3(5.5) 42.4(11.4) 44.2(12.1) 
Mother alive, n(%) 203(95.1) 190(99.0) 223(98.2) 229(99.1) 
Father alive, n(%) 200(99.5) 190(100.0) 221(98.2) 227(98.3) 
Mother's main income from farming own land, n(%) 153(75.0) 150(77.3) 159(68.9) 171(73.1) 
Nutrition parameters (all) 
Mid-Upper Arm Circumference (cm), Mean(SD) 10.9(0.8) 10.9(1.0) 11.5(1.0) 11.3(0.9) 
Weight (kg), Mean (SD) 6.2(1.1) 6.3(1.2) 8.8(1.6) 8.6(1.6) 
Length/Height (cm),  Mean(SD) 67.2(5.0) 67.2(5.2) 80.2(7.8) 80.1(7.5) 
Bilateral pitting edema, n(%) 26(12.5) 26(13.2) 69(29.9) 57(24.0) 
Weight-for-age Z-score, Mean(SD) -4.0(1.0) -3.9(1.2) -4.2(1.0) -4.4(0.9) 
Height-for-age Z-score, Mean(SD) -4.3(1.5) -4.0(1.6) -4.8(1.4) -5.0(1.4) 
Weight-for-height Z-score, Mean(SD) -2.4(1.1) -2.4(1.2) -2.2(1.3) -2.4(1.3) 
Nutrition parameters (children without edema) n=180 n=170 n=162 n=180 
Mid-Upper Arm Circumference (cm), Mean(SD) 10.8(0.6) 10.8(0.8) 11.1(0.5) 11.1(0.4) 
Weight (kg), Mean (SD) 6.1(1.0) 6.1(1.1) 8.5(1.4) 8.5(1.3) 
Length/Height (cm),  Mean(SD) 66.7(4.7) 66.6(5.0) 79.9(7.9) 79.9(7.7) 
Weight-for-age Z-score, Mean(SD) -4.1(1.0) -4.0(1.1) -4.4(0.8) -4.5(0.9) 
Height-for-age Z-score, Mean(SD) -4.3(1.5) -4.1(1.7) -4.9(1.5) -5.0(1.4) 
Weight-for-height Z-score, Mean(SD) -2.5(1.1) -2.5(1.1) -2.5(1.1) -2.6(1.1) 
Nutrition parameters (children with edema) n=28 n=27 n=69 n=57 
Mid-Upper Arm Circumference (cm), Mean(SD) 11.6(1.5) 11.9(1.5) 12.3(1.2) 12.0(1.5) 
Weight (kg), Mean (SD) 7.2(1.4) 7.5(1.4) 9.6(1.9) 9.2(2.0) 
Length/Height (cm),  Mean(SD) 70.5(5.9) 71.1(4.3) 81.1(7.3) 80.9(6.7) 
Weight-for-age Z-score, Mean(SD) -3.4(1.2) -3.2(1.3) -3.6(1.1) -4.1(1.1) 
Height-for-age Z-score, Mean(SD) -3.9(1.7) -3.7(1.4) -4.6(1.3) -4.9(1.2) 
Weight-for-height Z-score, Mean(SD) -1.9(1.3) -1.7(1.6) -1.5(1.1) -1.9(1.1) 
1SMS-RUTF=Soya-Maize-Sorghum Based Ready-To-Use Therapeutic Food; 2P-RUTF= Peanut 
paste based Ready-To-Use Therapeutic Food 
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Table 4: Comparison of overnight-fasted concentrations of selected amino acids at baseline and at discharge  
 
Control
1
 (A) SMS-RUTF
2
(B) P-RUTF
3
(C)
 
Comparisons (p-values)
4
 
Amino Acid Median(IQR
5
) Median(IQR) Median(IQR) A versus B A versus C B versus C 
Admission n=25 n=30 n=30 
   
Lysine (µmol/l) 102.81(87.49, 142.21) 70.59(44.08, 102.99) 81.80(43.92, 112.06) 0.004 0.009 0.496 
Valine (µmol/l) 124.51(103.47 ,  161.08) 90.89(57.23, 113.46) 103.91(75.59, 125.41) <0.001 0.008 0.117 
Methionine (µmol/l) 16.54(13.27,  20.30) 10.99(7.22, 15.27) 12.83(10.18, 15.05) <0.001 0.004 0.178 
Cystine (µmol/l) 25.62(20.73,  28.58) 10.48(6.49, 16.98) 16.32(9.08, 21.29) <0.001 <0.001 0.158 
Tyrosine (µmol/l) 45.61(41.60,  52.92) 22.35(11.45, 34.81) 30.36(22.13,  41.68) <0.001 <0.001 0.209 
Tryptophan (µmol/l) 15.41(7.66,  19.20) 4.27(2.50, 9.28) 4.14(2.23,  9.62) <0.001 0.003 0.685 
Phenylalanine (µmol/l) 47.22(41.21,  58.15) 37.67(25.68, 52.43) 39.94(29.34,  55.24) 0.030 0.063 0.469 
Discharge n=25 n=20 n=26 
   
Lysine (µmol/l) 102.81(87.49, 142.21) 109.22(85.67, 144.31) 99.44(84.81, 144.84) 0.819 0.880 0.690 
Valine (µmol/l) 124.51(103.47, 161.08) 117.50(98.27,  139.60) 127.08(103.98, 159.80) 0.385 0.985 0.506 
Methionine (µmol/l) 16.54(13.27,  20.30) 13.61(10.48, 15.01) 14.56(11.97, 16.28) 0.005 0.048 0.268 
Cystine (µmol/l) 25.62(20.73, 28.58) 24.96(16.70, 34.08) 35.60(29.00, 39.04) 0.715 <0.001 0.004 
Tyrosine (µmol/l) 45.61(41.60, 52.92) 39.07(30.36, 54.77) 48.00(41.54, 71.04) 0.537 0.258 0.092 
Tryptophan (µmol/l) 15.41(7.66, 19.20) 13.24(8.26, 20.68) 20.13(13.15, 31.61) 0.784 0.024 0.092 
Phenylalanine (µmol/l) 47.22(41.21, 58.15) 39.72(33.29, 54.74) 43.57(38.75, 66.60) 0.144 0.638 0.215 
Summary statistics are median and interquartile range;1Community controls were surveyed only once and the same data is used for comparison 
with admission and discharge data; 2SMS-RUTF, Soya-Maize-Sorghum Based Ready-To-Use Therapeutic Food; 3P-RUTF, Peanut based Ready-
To-Use Therapeutic Food; 4Mann-Whitney test with Bonferroni correction (difference statistical significant if p<0.017); 5IQR, interquartile range
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Table 5: Between group comparison at discharge and with community controls of body composition parameters measured by deuterium dilution technique  
 Control
3
(A) SMS-RUTF
4
 (B) P-RUTF
5
 (C)   Comparison
6
 B versus A Comparison
6
 C versus A Comparison
6
 B versus C 
Variables Mean±SD Mean±SD Mean±SD Difference (95%CI
7
) p-value Difference (95%CI) p-value Difference (95%CI) p-value 
n 47 29 26       
Age (months) 36.53±18.7 40.75±17.7 33.6±19.0 4.2(-4.4, 12.8) 0.332 -2.9(-12.0, 6.3) 0.534 7.1(-2.8, 17.0) 0.158 
Weight (kg) 11.5±2.5 10±2.1 9.2±2.3 -1.5(-2.6,-0.4) 0.010 -2.3(-3.5,  -1.1) <0.001 0.8(-0.4, 2.0) 0.174 
Height (cm) 84.5±9.8 79.5±8.6 77.1±9.8 -5.0(-9.7,-0.4) 0.033 -7.5(-12.5,-2.5) 0.004 2.4(-2.5, 7.4) 0.321 
MUAC
1
 (cm) 14.3±1.2 13.3±0.8 13.1'±0.7 -1.0(-1.4, -0.4) <0.001 -1.1(-1.6, -0.6) <0.001 0.2(-0.2, 0.6) 0.260 
WAZ
2
 -1.47±0.94 -3.06±0.79 -3.02±0.94 -1.59(-2.03, -1.15) <0.001 -1.54(-2.02, -1.07) <0.001 -0.05(-0.51, 0.42) 0.842 
HAZ
2
 -2.54±1.48 -4.56±085 -4.12±1.45 -2.02(-2.58, -1.45) <0.001 -1.59(-2.27, -0.90) <0.001 -0.44(-1.07, 0.20) 0.177 
WHZ
2
 0.02±0.86 -0.44±0.97 -0.77±0.69 -0.46(-0.88, -0.04) 0.033 -0.79(-1.18, -0.40) <0.001 0.33(-0.13, 0.79) 0.157 
Fat Free mass (kg) 9.4±2.6 8.1±2.2 7.6±1.8 -1.3(-2.4, -0.1) 0.034 -1.8(-2.9, -0.6) 0.003 0.5(-0.6, 1.6) 0.341 
Body Fat mass (kg) 2.1±1.0 1.9±0.9 1.6±0.9 -0.2(-0.7, 0.2) 0.374 -0.5(-1.0, -0.0) 0.041 0.3(-0.2, 0.8) 0.245 
Percentage fat (%) 19.2±9.2 19.7±9.3 17.3±7.3 0.5(-3.9, 4.8) 0.825 -1.9(-6.1, 2.3) 0.369 2.4(-2.2, -7.0) 0.300 
Fat Free mass index
8
 (kg/m
2
) 12.9±1.1 12.7±1.7 12.6±1.1 -0.2(-0.8, 0.4) 0.535 -0.3(-0.8, 0.2) 0.274 0.1(-0.7, 0.9) 0.802 
Fat mass index
9
 (kg/m
2
) 3.1±1.0 3.1±1.5 2.7±1.0 0.0(-0.6, 0.6) 0.999 -0.4(-0.9, 0.1) 0.111 0.4(-0.3, 1.1) 0.262 
Summary statistics are means and standard deviation;1MUAC, Mid-Upper Arm Circumference; 2Anthropometric indice weight-for-age Z-score (WAZ), height-
for-age Z-score (HAZ) and Weight-for-height Z-score (WHZ); 3Control (A) are non-wasted children with no history of severe acute malnutrition recruited to 
serve as community controls; 4SMS-RUTF (B), Soya-Maize-Sorghum ready-to-use therapeutic food group; 5P-RUTF(C), standard peanut and milk based 
ready-to-use therapeutic food group; 6t-test analysis with Bonferroni correction (difference statistical significant if p<0.017); 7CI, confidence interval; 8Fat Free 
mass index, Fat Free mass relative to height obtained by dividing the Fat Free mass (in kg) to the height (in m); 9Fat mass index, Body fat  mass relative to 
height obtained by dividing the body fat mass (in kg) to the height (in m). 
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Table 6: Between group comparison of bio-electrical impedance analysis parameters of children at time of 
discharge from therapeutic feeding program 
  SMS-RUTF
1
 
P-RUTF
2
 
Difference
3
 
Parameter Mean±SD Mean±SD estimate (95% CI
4
) p-value 
n=73 n=90 
At admission 
Age (month) 43.85 ±11.74 42.38 ±13.67 1.47 (-2.52, 5.46) 0.468 
Weight(kg) 9.12 ±1.48 8.69 ±1.50 0.43 (-0.04, 0.89) 0.071 
Height (cm) 81.69 ±7.52 79.76 ±7.33 1.93 (-0.37, 4.24) 0.1 
MUAC
5
 (cm) 11.7 ±0.8 11.5 ±0.8 0.2 (-0.0, 0.5) 0.057 
At discharge 
      
Age (month) 45.94 ±11.91 45.30 ±14.97 0.64 (-3.62, 4.90) 0.767 
Weight(kg) 10.43 ±1.53 10.46 ±1.1.69 -0.03 (-0.53, 0.47) 0.902 
Height (cm) 82.41 ±7.40 80.55 ±7.28 1.86 (-0.41, 4.13) 0.109 
MUAC
5
 (cm) 13.4 ±0.7 13.6 ±0.8 -0.2 (-0.4. 0.0) 0.094 
Fat Free Mass (kg) 8.50 ±1.21 8.58 ±1.11 -0.08 (-0.44, 0.29) 0.661 
Fat Mass (kg) 1.93 ±0.81 1.88 ±0.78 0.05 (-0.21, 0.29) 0.69 
Percentage Fat Mass (%) 17.6±6.0 18.0±6.0 -0.4(-2.27, 1.47) 0.672 
Fat Free Mass Index
6
  (Kg/m2) 12.7 ±1.1 13.2 ±1.1 -0.5 (-0.85, -0.15) 0.006 
Fat Mass Index
7
  (Kg/m2) 2.74 ±1.03 2.96 ±1.17 -0.22 (-0.56, 0.13) 0.21 
Phase angle (degree) 3.47 ±0.51 3.74 ±0.53 -0.26 (-0.43, -0.10) 0.002 
Resistance (Ohms) 959 ±91 923 ±95 35 (7,  65) 0.016 
Reactance (Ohms) 57.92 ±10.32 60.33 ±10.23 -2.41 (-5.60, 0.79) 0.138 
Illness marker  0.957 ±0.007 0.95 ±0.013 0.006 (0.003, 0.009) <0.001 
Resistance/Height (Ohm/cm) 1172 ±151 1156 ±166 15.66 (- 34.98, 65.31) 0.534 
Reactance/Height (Ohm/cm) 70.47 ±12.25 75.45 ±14.42 -4.99 (-9.18, -0.79) 0.02 
Summary statistics are means and standard deviation (SD);1SMS-RUTF (B), Soya-Maize-Sorghum Ready-
to-Use Therapeutic Food group; 2P-RUTF(C), Peanut based Ready-to-Use Therapeutic Food group; 3t-test 
analysis; 4CI, confidence interval; 5MUAC, Mid-Upper Arm Circumference; 6Fat Free mass index, Fat Free 
mass relative to height obtained by dividing the Fat Free mass (in kg) to the height (in m); 7Fat mass index, 
Body fat  mass relative to height obtained by dividing the body fat mass (in kg) to the height (in m). 
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Figures’ legends 
 
Figure 1: study participants flow diagram 
ITT, Intention-to-Treat; LOS, Length of Stay; PP, Per Protocol; RUTF, Ready-to-Use Therapeutic Food; P-
RUTF, Peanut based Ready-to-Use Therapeutic Food; SMS-RUTF, Soya-Maize-Sorghum Ready-to-Use 
Therapeutic Food 
 
Figure 2: Intention-To-Treat analysis:  difference in recovery rate between the Soya-Maize-Sorghum 
Ready-to-Use Therapeutic Food and Peanut based Ready-to-Use Therapeutic Food for both age 
groups 
 
Comparison of the difference in estimated marginal means and their bootstrapped 95% CI, The n 
indicate the total n for the RUTF group, the n for children 6-23 months and the n for children 24 to 59 
months;  
 
Figure 3: Per Protocol analysis:  difference in recovery rate between the Soya-Maize-Sorghum 
Ready-to-Use Therapeutic Food and Peanut based Ready-to-Use Therapeutic Food for both age 
groups 
 
Comparison of the difference in estimated marginal means and their bootstrapped 95% CI; The n 
indicate the total n for the RUTF group, the n for children 6-23 months and the n for children 24 to 59 
months 
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Figure 4: Per protocol analysis: difference in daily weight gain between the Soya-Maize-Sorghum 
Ready-to-Use Therapeutic Food and Peanut based Ready-to-Use Therapeutic Food for both age 
groups 
 
Comparison of the difference in estimated marginal means and their bootstrapped 95% CI; The n 
indicate the total n for the RUTF group, the n for children 6-23 months and the n for children 24 to 59 
months 
 
 
Figure 5: difference in length of stay between the Soya-Maize-Sorghum Ready-to-Use Therapeutic 
Food and Peanut based Ready-to-Use Therapeutic Food for both age groups in intention-to-treat 
analysis and for the recovered children 
 
Comparison of the difference in estimated marginal means and their bootstrapped 95% CI; The n 
indicate the total n for the RUTF group, the n for children 6-23 months and the n for children 24 to 59 
months  
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Figure 1: study participants flow diagram  
Assessed for eligibility (n= 924) 
Excluded (n= 38) 
♦   Not meeting inclusion criteria (n=2) 
♦   Declined to participate (n= 12) 
♦   Group assignment not random (n=6) 
♦   Admission by unqualified staff (n=19) 
Analysed 
ITT analyses =439(208/231) 
PP analysis: recovery rate: n=353 (143/210) 
♦ Exclude self-discontinued n=69(51/18) 
PP analysis: weight gain and LOS=317(113/204) 
♦ Include only those discharged as cured  
♦ Exclude deaths [n=11(7/4)] and Non-
respondents [n=25(23/2)] 
Per protocol discharge =353 (143/210) 
Self-discontinuation =69 (51/18) 
Programme termination =17 (14/3)  
SMS-RUTF 
Allocated to intervention = 445 (212/233) 
♦ Received allocated RUTF=439(208/231) 
♦ Post first day refusal = 6 (4/2) 
Per protocol discharge =378 (161/217) 
Self-discontinuation =49 (31/18) 
Programme termination =9 (7/2)  
P-RUTF 
Allocated to intervention =441 (202/239) 
♦ Received allocated RUTF=436(199/237) 
♦ Post first day refusal = 5 (3/2) 
Analysed 
ITT analyses = 436(199/237) 
PP analysis: recovery rate=378 (161/217) 
♦ Exclude self-discontinued [n=49(31/18)] 
and because still on treatment at 
programme end [n=9(7/2)] 
PP analysis: weight gain and LOS=362(148/214) 
♦ Include only those discharged as cured  
♦ Exclude deaths [n=5(4/1)] and Non-
respondents [n=11(9/2)] 
Allocation 
Analysis 
Follow-Up 
Randomized to RUTF groups (n=886) 
(0-23 month=414 /≥24 months=472) 
Enrollment 
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6-23 months
24-59 months
-10.0-30.0 10.00.0-20.0
Difference in recovery rate in percentage and 95% confidence interval
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Figure 2: Intention-To-Treat analysis:  difference in recovery rate between the Soya-
Maize-Sorghum Ready-to-Use Therapeutic Food [n=439(208/231)] and Peanut based 
Ready-to-Use Therapeutic Food [n=436(199/237)] for both age groups 
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Figure 3: Per Protocol analysis:  difference in recovery rate between the Soya-Maize-
Sorghum Ready-to-Use Therapeutic Food [n=353(143/210)] and Peanut based Ready-
to-Use Therapeutic Food [n=378(161/217)] for both age groups 
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Figure 4: Per protocol analysis: difference in daily weight gain between the Soya-
Maize-Sorghum Ready-to-Use Therapeutic Food [n=317(113/204)] and Peanut based 
Ready-to-Use Therapeutic Food [n=362(148/214)] for both age groups 
 
 
 
24-59 months
6-23 months
-1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4
Difference in weight gain in g/kg/day and 95% confidence interval
Inferiority Zone Non-inferiority zone 
 The American Journal of Clinical Nutrition AJCN/2015/119537 Version 2
 24-59 months
6-23 months
A
Intention-to-treat
-21.0 -14.0 -7.0 0.0 7.0 21.014.0
Difference in length of stay in days and 95% confidence interval
24-59 months
6-23 months
Recovered children
B
-21.0 -14.0 -7.0 0.0 7.0 14.0 21.0
Difference in length of stay in days and 95% confidence interval
Non-inferiority zone 
Non-inferiority zone 
Inferiority 
zone 
Inferiority zone 
 Figure 5: difference in length of stay between the Soya-Maize-Sorghum Ready-to-Use Therapeutic Food [n=439(208/231)] and Peanut based Ready-
to-Use Therapeutic Food [n=436(199/237)] for both age groups in intention-to-treat analysis (A) and difference between recovered children (B) of  the 
Soya-Maize-Sorghum Ready-to-Use Therapeutic Food group [n=317(113/204)] and Peanut based Ready-to-Use Therapeutic Food [n=362(148/214)] 
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